Business Wire

Led by Oncology Sector, Life Sciences Deal Market Value Increases in 2017 Despite Downward Trend in Deal Volume

Jaa

Clarivate Analytics, the global leader in providing trusted insights and analytics to accelerate the pace of innovation, has revealed that the market value of the most innovative and impactful global life sciences transactions of 2017 increased by 6% totaling US $364 billion, despite a decrease in overall deal volume. The transactions nominated for the annual Clarivate Cortellis Deal of the Year Awards include licensing and mergers and acquisitions. The announcement of the nominees at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco coincided with the Clarivate Deals and Portfolio Annual Review presentation – the foremost independent analysis of the economic trends shaping the life sciences sector in 2017.

Clarivate’s Deals and Portfolio Annual Review showcased a deep-dive analysis of 4,234 life sciences transactions. While overall the aggregate dollar value for deals increased from 2016, deal volume dropped by approximately 3% and saw contractions in almost every type of deal structure. This represents a reversal from last year when deal volume was up, but deal dollars were down.

“There is a healthy appetite for acquisitions and strong liquidity for deals in today’s market, but several factors contributed to deal volume falling below the last two years,” said Laura Vitez, commercial insights manager at Clarivate. “2017 saw a stronger IPO market for biopharma than the previous year, which meant companies had more viable alternatives to stay independent. We also experienced high valuations that resulted in heightened expectations during deal discussions. Finally, we saw many U.S. companies take a wait-and-see approach as the prospects for corporate tax reform played out right up to the end of the year.”

A total of ten Deal of the Year nominees was announced, five each in the categories of M&A and licensing. They include some of the industry’s most recognizable names (AstraZeneca, Celgene, and Merck) and life sciences upstarts like Rigontec, CureVac, and IFM Therapeutics. Nominees were recognized for innovations in creative deal structures, the use of novel technology, addressing unmet medical needs and new market penetrations. The analysis was drawn from the Cortellis suite of solutions from Clarivate Analytics. Industry participants may vote for the Deals of the Year at http://info.clarivate.com/DOTY. Winners will be announced in the beginning of February 2018.

Vitez added: “2018 shows promise for significant deal making, driven in large part by the lower corporate tax rates and tax repatriation allowances that were included in the final U.S. tax bill signed in December. U.S. biopharma companies comprise one-third of the top U.S. companies’ offshore cash holdings. When combined with the new lower corporate tax rates, we anticipate a considerable amount of the tax savings and repatriated cash will be used for M&A activities.”

This year’s Deals and Portfolio Review included a particularly deep investigation into oncology trends, which account for the largest number of M&A transactions by therapeutic area and the largest volume of licensing transactions. All but one of the top 20 dealmakers were active in oncology transactions last year.

“Oncology deals represented more than three times as many deals as neuroscience, the next most prevalent therapeutic area,” said Jaime Munro, global practice leader for portfolio and licensing at Clarivate. “Interestingly, we are seeing a trend of oncology deals focusing on earlier stages, with discovery and preclinical assets the focus of nearly two-thirds of oncology deals.”

2017 Deal of the Year nominees are:

M&A

J&J/Actelion
Johnson & Johnson agreed to acquire Actelion in a $30 billion deal that is second in size only to the 2009 Roche/Genentech merger in pharma and biotech M&A. J&J gains the worldwide rights to ponesimod and cadazolid, while Actelion spins out its research and early-stage assets into a new company.

Bioverativ/True North
Bioverativ acquired True North, a private, clinical stage company focused on candidates for complement-mediated diseases, for $825 million total with $400 million upfront. This early acquisition, which included $425 million in milestones, strengthens innovation in a rare blood disease.

BMS/IFM Therapeutics
In a deal that had everything – a young firm, cool technology and a spinout – BMS acquired IFM for $2.32 billion, with $300 million upfront. The cancer sector deal includes $1.01 billion in milestones for IFM’s preclinical STING (simulator of interferon genes) and NLRP3 agonist programs.

Gilead/Kite
Gilead acquired Kite, a developer of cell therapies for cancer treatment that express either a chimeric antigen receptor (CAR) or an engineered T-cell receptor (TCR), depending on the cancer type. This transformative $11.9 billion deal brings immuno-oncology to the forefront at Gilead.

Merck/Rigontec
Merck acquired Rigontec, a University of Bonn spinout focused on developing retinotic acid-inducible gene 1 (RIG-1) targeting therapies for various tumors. The $552.3 million acquisition was a smartly structured early sale, and RIG-1 has potential with Merck’s Keytruda.

Licensing

AstraZeneca/Pieris
The companies entered into a $2.145 billion deal that included $45 million upfront, under which AstraZeneca would develop and commercialize inhaled respiratory drugs, including PRS-060, using Pieris's Anticalin platform for respiratory diseases. The transaction leverages a novel technological modality with multiple co-development opt-ins.

Celgene/BeiGene
Celgene and BeiGene entered into a licensing agreement to develop and commercialize cancer drug BGB-A317 to combat solid tumors. The $1.292 billion deal includes $263 million in upfront cash and a $150 million equity stake. The deal is a win for both companies, as Celgene gets a PD-1 for its immuno-oncology backbone, while BeiGene gains an instant China portfolio.

Amgen/CytomyX
This creatively structured $1.668 billion discovery stage licensing deal includes $40 million in upfront cash and $20 million in equity for the development of T-cell engaging bispecific antibodies against EGFR and certain immuno-oncology targets worldwide.

Eli Lilly/CureVac
Eli Lilly licensed CureVac’s RNActive technology for the development and commercialization of up to five cancer vaccine products worldwide. A $1.803 billion deal with $50 million upfront and a $53 million equity stake, this is CureVac's largest collaboration to date, highlighting the industry's move toward targeting neoantigens.

AbbVie/Alector
Under this discovery stage deal, AbbVie will develop and commercialize Alector's immune therapies against Alzheimer’s disease and other neurodegenerative disorders worldwide. It works toward the promise of immuno-neurology by targeting microglia and macrophages – immune cells in the brain. The $225 million announcement includes $205 million upfront and $20 million in equity.

About Clarivate Analytics
Clarivate™ Analytics is the global leader in providing trusted insights and analytics to accelerate the pace of innovation. Building on a heritage going back more than a century and a half, we have built some of the most trusted brands across the innovation lifecycle, including the Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor® and Techstreet™. Today, Clarivate Analytics is a new and independent company on a bold entrepreneurial mission, to help our clients radically reduce the time from new ideas to life-changing innovations. For more information, please visit clarivate.com.

Contact information

Clarivate Analytics
Jason Milch, 312-379-9406
jmilch@baretzbrunelle.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza16.8.2018 08:00Tiedote

BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, today announced that it has entered into a multi-year research and development (R&D) collaboration with Pfizer Inc. (NYSE: PFE) to develop mRNA-based vaccines for prevention of influenza (flu). Under the terms of the agreement, BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines. Pfizer will assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines, following BioNTech’s completion of a first in human clinical study. BioNTech will receive $120 million in upfront, equity and near-term research payments and up to an additional $305 million in potential development, regulatory and commercial milestone payments. In addition, BioNTech will receive up to double-digit tiered royalty payments associated with worldwide sales if the program reac

Maxion Wheels to Showcase Market-Leading Light Weight Commercial Vehicle Wheels at REIFEN 201816.8.2018 07:05Tiedote

Maxion Wheels, the world’s largest producer of wheels, announced today its participation in REIFEN, the leading tire and wheel industry event in Europe, from Sept. 11 – 15, 2018 in Hall 12.1 / Stand D24. For the first time, REIFEN will be co-located with Automechanika Frankfurt at the Messe Frankfurt. “REIFEN is the premier event for European tire and wheel manufacturers and resellers, bringing us together to meet and collaborate on the important aftermarket themes of innovation, service and delivery,” stated Mark Gerardts, Vice President of Global Sales and Marketing, Maxion Wheels. “After a highly popular launch to truck and trailer OEMs in 2017, we’re excited to have the industry’s lightest mass production steel wheel now available to our aftermarket distributors. This wheel, along with several others, including our new 10.00W-20 wide base tubetype and tubeless heavy duty armored vehicles wheel are great examples of our continued efforts to bring our OE multi-application innovations

Lenovo Accelerates Turnaround with Back-to-Back, Double-Digit Quarterly Revenue Growth16.8.2018 02:40Tiedote

Lenovo Group (HKSE: 0992) (PINK SHEETS: LNVGY) today announced results for its first fiscal quarter ended June 30, 2018. For the second straight quarter, Lenovo achieved strong double-digit growth in revenue year-on-year. Group revenue reached US$11.91 billion, up 19% year-on-year. The company also reported strong pre-tax income during the quarter of US$113 million, an improvement of US$182 million year-on-year, as profitability improved across all businesses. In the first fiscal quarter, Lenovo’s profit attributable to equity holders grew to US$77 million, up US$149 million year-over-year. Basic earnings per share in the first fiscal quarter was 0.65 US cents or 5.10 HK cents. “As we persistently execute our 3-wave strategy, all our businesses made solid improvements in both revenue and profitability. Lenovo has passed the turning point and entered a phase of ‘acceleration’ - accelerating the execution of our transformation strategy and accelerating the rising momentum in business per

CORRECTING and REPLACING Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy16.8.2018 01:37Tiedote

Please replace the release with the following corrected version due to multiple revisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) The corrected release reads: EBOLA SUCCESSFULLY NEUTRALIZED BY LATEST GENERATION POLYCLONAL IMMUNOTHERAPY Promising new platform can rapidly respond to emerging infectious diseases Sioux Falls, SD, August 15, 2018 – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted at the Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of He

QConnect – Markkinoiden älykkäin, erittäin kompakti ja lujatekoinen viestintälaite15.8.2018 23:23Tiedote

Quake Global, Inc. (QUAKE), yksi maailman johtavista IoT-markkinoiden toimittajista, julkaisi QConnect™, uuden sukupolven kehittyneen telematiikkalaitteen. Äärimmäisen kompakti QConnect integroituu kiinteisiin ja liikkuviin omaisuuksiin niiden seuraamiseksi, valvomiseksi ja hallitsemiseksi reaaliajassa mistä ja milloin tahansa. Laite tarjoaa useita pitkälle kehitettyjä langattomia kommunikaatiovaihtoehtoja, mukaan lukien LTE/2G/3G, kaksitaajuus-Wi-Fi, Bluetooth/BLE, V2X ja satelliitti. Laite on suunniteltu vastaamaan moniin eri vaatimuksiin yksinkertaisista ja edullisista seurantasovelluksista aina korkean suorituskyvyn monikanavaisiin videon suoratoistosovelluksiin. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20180815005706/fi/ Quake Global’s new QConnect, the most intelligent, global, ultra-compact and rugged communication device available (Photo: Business Wire) QConnect tarjoaa joustavuutta sen ainutlaatuisilla sovell

Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 20:43Tiedote

SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted by the National Interagency Confederation for Biological Research and other collaborators including United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Naval Medical Research Center (NMRC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) According to the World Health Organization, Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans with an average fatality rate around 50%.

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme